13F-HR filed by Venrock Adviser, LLC
Venrock Adviser, LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-14, with 29 holding rows worth $622,862,338.
- Accession
- 0001104659-23-022010
- Filer
- CIK 1615982
- Filed
- 2023-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2022
A holdings report, 29 entries on the cover page, a total value of $622,862,338 stated on the cover page (in dollars after the unit check, H1), rows summing to $622,862,338 with VALUE read as dollars as filed, 13F file number 028-20281. A later restatement replaced it, so the quarter does not use it. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 2,699,865 | $78,863,057 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 4,563,962 | $71,882,402 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 670,718 | $51,732,479 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 4,038,117 | $46,680,633 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 3,707,891 | $37,746,330 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 3,517,125 | $34,186,455 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 2,105,386 | $29,496,458 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J101 | ADR | 9,300,000 | $29,257,800 | dollars as filed | |
| DICE THERAPEUTICS INC | 23345J104 | COM | 819,000 | $25,552,800 | dollars as filed | |
| AEROVATE THERAPEUTICS INC | 008064107 | COM | 747,869 | $21,912,562 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 1,080,000 | $20,876,400 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 2,916,667 | $19,716,669 | dollars as filed | |
| NOVAVAX INC | 670002401 | COM NEW | 1,879,894 | $19,325,310 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 1,226,214 | $18,969,531 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 1,895,285 | $17,531,386 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 3,220,050 | $16,647,659 | dollars as filed | |
| VECTIVBIO HLDG AG | H9060V101 | COM | 1,866,000 | $16,168,890 | dollars as filed | |
| PROVENTION BIO INC | 74374N102 | COM | 1,118,653 | $11,824,162 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 6,351,531 | $9,844,873 | dollars as filed | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 2,208,812 | $8,746,896 | dollars as filed | |
| LIANBIO ADR | 53000N108 | COM | 4,793,047 | $7,860,597 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 1,770,705 | $7,047,406 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 3,050,022 | $5,886,542 | dollars as filed | |
| FULCRUM THERAPEUTICS INC | 359616109 | COMMON STOCK | 447,326 | $3,256,533 | dollars as filed | |
| LYRA THERAPEUTICS INC | 55234L105 | COM | 924,170 | $2,901,894 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 2,709,987 | $2,845,486 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 1,171,436 | $2,565,445 | dollars as filed | |
| AFFIMED N V | N01045108 | COM | 1,428,571 | $1,771,428 | dollars as filed | |
| RALLYBIO CORP | 75120L100 | COM | 268,532 | $1,764,255 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-23-022010 | this filing | 2023-02-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001104659-23-060789 | base | 2023-05-15 | acceptance time not in the bulk data set |